Effective weight loss after treatment with a glucagon-like peptide-1 receptor agonist in a morbidly obese and diabetic patient before bariatric surgery: a case report

Journal of Medical Case Reports

Chien-Hsing Lee¹  Wen-Hao Tang¹  Jui-Hung Chen¹ 

[1] Division of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, No. 325, Sec. 2, ChengGong Rd, NeiHu District, Taipei City 114, Taiwan

关键词: Morbid obesity;    GLP-1 receptor agonist;    Diabetes;    Bariatric surgery;   

Others  :  1181048
DOI  :  10.1186/1752-1947-8-304

 received in 2014-02-19, accepted in 2014-07-15,  发布年份 2014

【 摘 要 】

Introduction

Glucagon-like peptide-1 receptor agonists, a new class of anti-diabetic drugs, are widely used in the treatment of type 2 diabetes. However, the effect of glucagon-like peptide-1 receptor agonists on the treatment of preoperative weight loss in obese type 2 diabetic patients has not been reported.

Case presentation

A 38-year-old Taiwanese woman presented to our hospital with morbid obesity and type 2 diabetes mellitus. Bariatric surgery was recommended by a general surgery specialist. Weight loss before surgery was recommended to reduce the frequency of surgical complications. In addition to diet control with lifestyle modifications, pharmacological treatment with metformin and glucagon-like peptide-1 receptor agonists was administered. Fourteen months of treatment reduced her hemoglobin A1c level from 7.4 to 5.5% and reduced her body weight by 21.2kg.

Conclusions

One year of diet control with lifestyle modifications and pharmacological treatment with glucagon-like peptide-1 receptor agonists and metformin markedly decreased hemoglobin A1c levels and resulted in effective and substantial weight loss in a morbidly obese patient with dysregulated diabetes during the preoperative period.

【 授权许可】

   
2014 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I: Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009, 122:248-256. e5
• [2]Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, Eid GM, Mattar S, Ramanathan R, Barinas-Mitchel E, Rao RH, Kuller L, Kelley D: Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003, 238:467-484. discussion 84–5
• [3]Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjostrom CD, Sullivan M, Wedel H, Swedish Obese Subjects Study Scientific, Group: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004, 351:2683-2693.
• [4]Benotti PN, Still CD, Wood GC, Akmal Y, King H, El Arousy H, Dancea H, Gerhard GS, Petrick A, Strodel W: Preoperative weight loss before bariatric surgery. Arch Surg-Chicago 2009, 144:1150-1155.
• [5]Livhits M, Mercado C, Yermilov I, Parikh JA, Dutson E, Mehran A, Ko CY, Gibbons MM: Does weight loss immediately before bariatric surgery improve outcomes: a systematic review. Surg Obes Relat Dis 2009, 5:713-721.
• [6]Vargas MA, Fernandez NC, Serrano JO: Preoperative weight loss in patients with indication of bariatric surgery: which is the best method? Nutr Hosp 2011, 26:1227-1230.
• [7]Nauck MA, Wollschlager D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B: Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM. Diabetologia 1996, 39:1546-1553.
• [8]Larsson H, Holst JJ, Ahren B: Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 1997, 160:413-422.
• [9]Assoc AD: Standards of medical care in diabetes-2013. Diabetes Care 2013, 36:S11-S66.
• [10]Adams JP, Murphy PG: Obesity in anaesthesia and intensive care. Brit J Anaesth 2000, 85:91-108.
• [11]VanGaal LF, Wauters MA, DeLeeuw IH: The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obesity 1997, 21:S5-S9.
• [12]Busetto L, Tregnaghi A, De Marchi F: Liver volume and visceral obesity in women with hepatic steatosis undergoing gastric banding. Obes Res 2002, 10:408-411.
• [13]Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A: Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011, CD006423.
• [14]Buse JB, Klonoff DC, Nielsen LL, Guan XS, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME: Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007, 29:139-153.
• [15]Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, Bicsak TA, Brodows RG, Kim DD: Long-term effects of exenatide therapy over 82 weeks on glycemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006, 8:419-428.